Clinical implications of HIV-1 minority variants

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1667-1674

  Li, Jonathan Z ^a   Kuritzkes, Daniel R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

HIV 1 drug resistance; minority variants; treatment failure

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; INTEGRASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS DNA;

ANTIVIRAL RESISTANCE; DRUG TREATMENT FAILURE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PHENOTYPE; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; TROPISM; VERTICAL TRANSMISSION; VIRUS REPLICATION;

HIV-1 DRUG RESISTANCE; MINORITY VARIANTS; TREATMENT FAILURE;

ANTI-RETROVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; KAPLAN-MEIER ESTIMATE; PHENOTYPE; REVERSE TRANSCRIPTASE INHIBITORS; TREATMENT FAILURE; VIRAL TROPISM;

EID: 84877255877     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit125     Document Type: Review

References (104)

1. Larder BA, Kohli A, Kellam P, Kemp SD, Kronick M, Henfrey RD. Quantitative detection of HIV-1 drug resistance mutations by automated DNA sequencing. Nature 1993; 365:671-3.
2. Church JD, Jones D, Flys T, et al. Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn 2006; 8:430-2; quiz 527.
3. Jain V, Sucupira MC, Bacchetti P, et al. Differential persistence of transmitted HIV-1 drug resistance mutation classes. J Infect Dis 2011; 203:1174-81.
4. Yanik EL, Napravnik S, Hurt CB, et al. Prevalence of transmitted anti-retroviral drug resistance differs between acutely and chronically HIV-infected patients. J Acquir Immune Defic Syndr 2012; 61:258-62.
5. Preston BD, Poiesz BJ, Loeb LA. Fidelity of HIV-1 reverse transcrip-tase. Science 1988; 242:1168-71.
6. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Marko-witz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-6.
7. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995; 267:483-9.
8. Gadhamsetty S, Dixit NM. Estimating frequencies of minority nevira-pine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model. J Virol 2010; 84:10230-40.
9. Paredes R, Marconi VC, Campbell TB, Kuritzkes DR. Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations. J Virol Methods 2007; 146:136-46.
10. Johnson JA, Li JF, Wei X, et al. Simple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutations. PLoS One 2007; 2:e638.
11. Boltz VF, Maldarelli F, Martinson N, et al. Optimization of allele-spe-cific PCR using patient-specific HIV consensus sequences for primer design. J Virol Methods 2010; 164:122-6.
12. Edelstein RE, Nickerson DA, Tobe VO, Manns-Arcuino LA, Frenkel LM. Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine. J Clin Mi-crobiol 1998; 36:569-72.
13. Archer J, Weber J, Henry K, et al. Use of four next-generation sequencing platforms to determine HIV-1 coreceptor tropism. PLoS One 2012; 7:e49602.
14. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999; 354:795-802.
15. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-7.
16. Eshleman SH, Guay LA, Mwatha A, et al. Characterization of nevira-pine resistance mutations in women with subtype A vs. D HIV-1 6-8 weeks after single-dose nevirapine (HIVNET 012). J Acquir Immune Defic Syndr 2004; 35:126-30.
17. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-5.
18. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 2005; 192:16-23.
19. Flys TS, Chen S, Jones DC, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42:610-3.
20. Hauser A, Mugenyi K, Kabasinguzi R, et al. Detection and quantification of minor human immunodeficiency virus type 1 variants harboring K103N and Y181C resistance mutations in subtype A and D isolates by allele-specific real-time PCR. Antimicrob Agents Chemo-ther 2009; 53:2965-73.
21. Wagner TA, Kress CM, Beck I, et al. Detection of HIV-1 drug resistance in women following administration of a single dose of nevira-pine: comparison of plasma RNA to cellular DNA by consensus sequencing and by oligonucleotide ligation assay. J Clin Microbiol 2010; 48:1555-61.
22. Pilger D, Hauser A, Kuecherer C, et al. Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis. Antivir Ther 2011; 16:109-13.
23. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS 2006; 20:995-1002.
24. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resis-tant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci USA 2006; 103:7094-9.
25. Hunt GM, Coovadia A, Abrams EJ, et al. HIV-1 drug resistance at an-tiretroviral treatment initiation in children previously exposed to single-dose nevirapine. AIDS 2011; 25:1461-9.
26. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevi-rapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis 2005; 192:24-9.
27. Hauser A, Mugenyi K, Kabasinguzi R, Kuecherer C, Harms G, Kunz A. Emergence and persistence of minor drug-resistant HIV-1 variants in Ugandan women after nevirapine single-dose prophylaxis. PLoS One 2011; 6:e20357.
28. Muro E, Droste JA, Hofstede HT, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr 2005; 39:419-21.
29. Lockman S, Hughes MD, McIntyre J, et al. Antiretroviral therapies in women after single-dose nevirapine exposure. N Engl J Med 2010; 363:1499-509.
30. Boltz VF, Zheng Y, Lockman S, et al. Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine. Proc Natl Acad Sci USA 2011; 108:9202-7.
31. Coovadia A, Hunt G, Abrams EJ, et al. Persistent minority K103N mutations among women exposed to single-dose nevirapine and viro-logic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. Clin Infect Dis 2009; 48:462-72.
32. Rowley CF, Boutwell CL, Lee EJ, et al. Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance. AIDS Res Hum Retroviruses 2010; 26:293-300.
33. MacLeod IJ, Rowley CF, Thior I, et al. Minor resistant variants in nevi-rapine-exposed infants may predict virologic failure on nevirapine-containing ART. J Clin Virol 2010; 48:162-7.
34. Lehman DA, Wamalwa DC, McCoy CO, et al. Low-frequency nevira-pine resistance at multiple sites may predict treatment failure in infants on nevirapine-based treatment. J Acquir Immune Defic Syndr 2012; 60:225-33.
35. McIntyre JA, Hopley M, Moodley D, et al. Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial. PLoS Med 2009; 6:e1000172.
36. Chi BH, Sinkala M, Mbewe F, et al. Single-dose tenofovir and emtrici-tabine for reduction of viral resistance to non-nucleoside reverse tran-scriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial. Lancet 2007; 370:1698-705.
37. Chi BH, Ellis GM, Chintu N, et al. Intrapartum tenofovir and emtricitabine reduces low-concentration drug resistance selected by single-dose nevirapine for perinatal HIV prevention. AIDS Res Hum Retroviruses 2009; 25:1099-106.
38. Lallemant M, Ngo-Giang-Huong N, Jourdain G, et al. Efficacy and safety of 1-month postpartum zidovudine-didanosine to prevent HIV-resistance mutations after intrapartum single-dose nevirapine. Clin Infect Dis 2010; 50:898-908.
39. Palmer S, Boltz VF, Chow JY, et al. Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women. Antivir Ther 2012; 17:327-36.
40. Hauser A, Sewangi J, Mbezi P, et al. Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission. PLoS One 2012; 7:e32055.
41. Micek MA, Blanco AJ, Carlsson J, et al. Effects of short-course zidovu-dine on the selection of nevirapine-resistant HIV-1 in women taking single-dose nevirapine. J Infect Dis 2012; 205:1811-5.
42. Van Dyke RB, Ngo-Giang-Huong N, Shapiro DE, et al. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-in-fected pregnant women receiving a single intrapartum dose of nevira-pine. Clin Infect Dis 2012; 54:285-93.
43. Balduin M, Oette M, Daumer MP, Hoffmann D, Pfister HJ, Kaiser R. Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naive patients and their impact on the viro-logical failure. J Clin Virol 2009; 45:34-8.
44. Geretti AM, Fox ZV, Booth CL, et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009; 52:569-73.
45. Goodman D, Zhou Y, Margot NA, et al. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy. AIDS 2011; 25:325-33.
46. Jakobsen MR, Tolstrup M, Sogaard OS, et al. Transmission of HIV-1 drug-resistant variants: prevalence and effect on treatment outcome. Clin Infect Dis 2010; 50:566-73.
47. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
48. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherent patients. Clin Infect Dis 2009; 48:239-47.
49. Metzner KJ, Rauch P, Braun P, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2011; 50:156-61.
50. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-71.
51. Peuchant O, Thiebaut R, Capdepont S, et al. Transmission of HIV-1 minority-resistant variants and response to first-line antiretroviral therapy. AIDS 2008; 22:1417-23.
52. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
53. Buckton AJ, Harris RJ, Pillay D, Cane PA. HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis. Antivir Ther 2010; 16:9-16.
54. Buckton AJ, Prabhu D, Motamed C, et al. Increased detection of the HIV-1 reverse transcriptase M184V mutation using mutation-specific minority assays in a UK surveillance study suggests evidence of unrecognized transmitted drug resistance. HIV Med 2010; 12:250-4.
55. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011; 305: 1327-35.
56. Li JZ, Paredes R, Ribaudo HJ, et al. Relationship between minority nonnucleoside reverse transcriptase inhibitor resistance mutations, adherence, and the risk of virologic failure. AIDS 2012; 26:185-92.
57. Papathanasopoulos M, Ketseoglou I, Travers S, et al. Antiretroviral drug-resistant minority variants are significantly associated with first-line treatment failure in antiretroviral drug-naive patients. In: International Workshop on HIV and Hepatitis Virus Drug Resistance and Curative Strategies, Sitges, Spain, 5-9 June 2012. Abstract 25.
58. Boltz VF, Bao Y, Lockman S, et al. The risk of virologic failure associated with low frequency nevirapine-resistant variants in women initiating nevirapine-containing ART varies depending on the history of exposure to sd-Nevirapine: OCTANE/ACTG 5208. In: 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8 March 2012. Abstract 105.
59. Garcia-Gonzalez C, Garcia-Bujalance S, Ruiz-Carrascoso G, et al. Detection and quantification of the K103N mutation in HIV reverse transcriptase by pyrosequencing. Diagn Microbiol Infect Dis 2012; 72:90-6.
60. Delobel P, Saliou A, Nicot F, et al. Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failure. PLoS One 2011; 6: e21655.
61. Hare CB, Mellors J, Krambrink A, et al. Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. Clin Infect Dis 2008; 47:421-4.
62. Le T, Chiarella J, Simen BB, et al. Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use. PLoS One 2009; 4:e6079.
63. Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201:672-80.
64. Lecossier D, Shulman NS, Morand-Joubert L, et al. Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005; 38:37-42.
65. Varghese V, Shahriar R, Rhee SY, et al. Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse tran-scriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors. J Acquir Immune Defic Syndr 2009; 52:309-15.
66. Codoner FM, Pou C, Thielen A, et al. Added value of deep sequencing relative to population sequencing in heavily pre-treated HIV-1-infected subjects. PLoS One 2011; 6:e19461.
67. Moyle GJ, Wildfire A, Mandalia S, et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 2005; 191:866-72.
68. Raymond S, Saliou A, Nicot F, et al. Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. AIDS 2011; 25:1668-70.
69. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-20.
70. Archer J, Braverman MS, Taillon BE, et al. Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 2009; 23:1209-18.
71. Tsibris AM, Korber B, Arnaout R, et al. Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One 2009; 4:e5683.
72. Archer J, Rambaut A, Taillon BE, Harrigan PR, Lewis M, Robertson DL. The evolutionary analysis of emerging low frequency HIV-1 CXCR4 using variants through time-an ultra-deep approach. PLoS Comput Biol 2010; 6:e1001022.
73. Baatz F, Struck D, Lemaire M, et al. Rescue of HIV-1 long-time archived X4 strains to escape maraviroc. Antiviral Res 2011; 92:488-92.
74. Swenson LC, Mo T, Dong WW, et al. Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 2011; 203:237-45.
75. Swenson LC, Mo T, Dong WW, et al. Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 2011; 53:732-42.
76. Kagan RM, Johnson EP, Siaw M, et al. A Genotypic Test for HIV-1 tropism combining Sanger sequencing with Ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One 2012; 7:e46334.
77. Lataillade M, Chiarella J, Yang R, et al. Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naive subjects in the CASTLE study. PLoS One 2010; 5: e10952.
78. Vignoles M, Barboni G, Agosti MR, et al. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina. Antivir Ther 2009; 14:1175-81.
79. Bansal V, Metzner KJ, Niederost B, et al. Minority K65R variants and early failure of antiretroviral therapy in HIV-1-infected Eritrean immigrant. Emerg Infect Dis 2011; 17:1966-8.
80. Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063-71.
81. Gianella S, Delport W, Pacold ME, et al. Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants. J Virol 2011; 85:8359-67.
82. Stekler JD, Ellis GM, Carlsson J, et al. Prevalence and impact of minority variant drug resistance mutations in primary HIV-1 infection. PLoS One 2011; 6:e28952.
83. D'Aquila RT, Geretti AM, Horton JH, et al. Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing. AIDS Res Hum Retroviruses 2011; 27:201-9.
84. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 inte-grase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203:1204-14.
85. Codoner FM, Pou C, Thielen A, et al. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure. Antiviral Res 2010; 88:281-6.
86. Charpentier C, Laureillard D, Piketty C, et al. High frequency of inte-grase Q148R minority variants in HIV-infected patients naive of inte-grase inhibitors. AIDS 2010; 24:867-73.
87. Liu J, Miller MD, Danovich RM, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretrovi-ral treatment. Antimicrob Agents Chemother 2011; 55:1114-9.
88. Ceccherini-Silberstein F, Van Baelen K, Armenia D, et al. Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors. Antimicrob Agents Chemother 2010; 54:3938-48.
89. Mukherjee R, Jensen ST, Male F, et al. Switching between raltegravir resistance pathways analyzed by deep sequencing. AIDS 2011; 25:1951-9.
90. Armenia D, Vandenbroucke I, Fabeni L, et al. Study of genotypic and phenotypic HIV-1 dynamics of integrase mutations during raltegravir treatment: a refined analysis by ultra-deep 454 pyrosequencing. J Infect Dis 2012; 205:557-67.
91. Nguyen H, Charpentier C, Nguyen N, et al. Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegra-vir-based regimens. HIV Med 2013.; 14:85-91.
92. Ross LL, Weinberg WG, DeJesus E, et al. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients. AIDS Res Hum Retroviruses 2010; 26:407-17.
93. Metzner KJ, Rauch P, Walter H, et al. Detection of minor populations of drug-resistant HIV-1 in acute seroconverters. AIDS 2005; 19:1819-25.
94. McKinnon JE, Delgado R, Pulido F, Shao W, Arribas JR, Mellors JW. Single genome sequencing of HIV-1 gag and protease resistance mutations at virologic failure during the OK04 trial of simplified versus standard maintenance therapy. Antivir Ther 2011; 16:725-32.
95. Fisher R, van Zyl GU, Travers SA, et al. Deep sequencing reveals minor protease resistance mutations in patients failing a protease inhibitor regimen. J Virol 2012; 86:6231-7.
96. Lataillade M, Chiarella J, Yang R, et al. Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing. PLoS One 2012; 7: e30118.
97. van Maarseveen N, Boucher C. Resistance to protease inhibitors. In: Geretti AM, ed. Antiretroviral resistance in clinical practice. London: Mediscript, 2006.
98. Tang MW, Shafer RW. HIV-1 antiretroviral resistance: scientific principles and clinical applications. Drugs 2012; 72:e1-25.
99. Colonno R, Rose R, McLaren C, Thiry A, Parkin N, Friborg J. Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens. J Infect Dis 2004; 189:1802-10.
100. Stelzl E, Proll J, Bizon B, et al. Human immunodeficiency virus type 1 drug resistance testing: evaluation of a new ultra-deep sequencing-based protocol and comparison with the TRUGENE HIV-1 Genotyp-ing Kit. J Virol Methods 2011; 178:94-7.
101. Dudley DM, Chin EN, Bimber BN, et al. Low-cost ultra-wide genotyp-ing using Roche/454 pyrosequencing for surveillance of HIV drug resistance. PLoS One 2012; 7:e36494.
102. De Wolf H, Van Marck H, Mostmans W, et al. HIV-1 nucleotide mixture detection in the virco((R))TYPE HIV-1 genotyping assay: a comparison between Sanger sequencing and 454 pyrosequencing. J Virol Methods 2011; 175:129-32.
103. Avidor B, Girshengorn S, Matus N, et al. Evaluation of a Benchtop HIV ultradeep pyrosequencing drug-resistance assay in the clinical laboratory. J Clin Microbiol 2013; 51:880-6.
104. Li JZ. Novel HIV-1 resistance and tropism testing. In: Cases on the Web. San Francisco, CA: IAS-USA, 2012. Available at: https://www. iasusa.org/cow.